Farren, Matthew R <br/><br/>
The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors.  [electronic resource] 

 -  Molecular cancer therapeutics  03 2017 
 - 417-427 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1538-8514 
<br/><br/><label>Standard No.: </label>10.1158/1535-7163.MCT-16-0498  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibodies, Monoclonal--pharmacology<br/>Antineoplastic Agents--pharmacology<br/>B7-H1 Antigen--antagonists & inhibitors<br/>CTLA-4 Antigen--antagonists & inhibitors<br/>Cell Line, Tumor<br/>Disease Models, Animal<br/>Dose-Response Relationship, Drug<br/>Drug Synergism<br/>Humans<br/>Hydrazines--pharmacology<br/>Immunomodulation--drug effects<br/>Karyopherins--antagonists & inhibitors<br/>Melanoma, Experimental<br/>Mice<br/>Neoplasms--drug therapy<br/>Receptors, Cytoplasmic and Nuclear--antagonists & inhibitors<br/>T-Lymphocytes--drug effects<br/>Triazoles--pharmacology<br/>Exportin 1 Protein